Carbazeran citrate

Cat. No.:	HY-108680
CAS No.:	153473-94-0
Molecular Formula:	$C_{24}H_{32}N_4O_{11}$
Molecular Weight:	552.53
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Carbazeran (citrate), a potent phosphodiesterase inhibitor, is aldehyde oxidase substrate. Carbazeran (citrate) can be used for the research of metabolic disease[1].
IC_{50} & Target	phosphodiesterase[1]
In Vivo	Carbazeran (10 mg/kg; p.o.) (citrate) of the unmetabolized in samples from humanized-liver mice, the mean plasma concentrations are lower than in those from control mice for 0.5~4 hours after oral administration[1]. Oral administration of carbazeran (citrate) to guinea pigs has reportedly resulted in large kinetic deuterium isotope effects on the AUC and C_{max}, without a change of systemic half-life[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice[1]
Dosage:	10 mg/kg
Administration:	P.o.
Result:	The mean plasma concentrations were lower than in those from control mice for 0.5~4 hours after oral administration.

REFERENCES

[1]. Uehara S, et al. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug Metab Dispos. 2020;48(7):580-586.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA